Log in to your Inderes Free account to see all free content on this page.

Demant

261.8

DKK

-0.61 %

DEMANT

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

13 following

-0.61%

-1.65%

-1.21%

-14.28%

-11.55%

-10.8%

-19.96%

+25.56%

+790.48%

Demant is a medical technology company. The company specializes in the development of hearing aids and hearing loops. The company operates worldwide, and the products are sold under various brands. The products are accessed via the company's distributors and sales channels. In addition to its main operations, the company conducts research in diagnostics for measuring hearing quality. The company was originally founded in 1904 and is headquartered in Smörum.

Market cap

57.88B DKK

Turnover

30.92M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

5.2.

2025

Annual report '24

6.3.

2025

General meeting '24

12.8.

2025

Interim report Q2'25

ShowingAll content types

Regulatory press release12/4/2024, 7:28 AM

Demant A/S: Financiel calendar 2025

Regulatory press release11/4/2024, 4:03 PM

Demant A/S: Interim Management Statement for Q3 2024

Regulatory press release9/16/2024, 8:30 AM

Demant A/S: Investor news - New President of Diagnostics and member of Demant Management

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release9/9/2024, 9:30 AM

Demant A/S: New staff-elected member of the Board of Directors

Regulatory press release8/19/2024, 1:16 PM

Demant A/S: Transactions with Demant shares by Board of Directors, Executive Board and their closely related parties

Regulatory press release8/14/2024, 4:34 PM

Demant A/S: Interim Report 2024

Regulatory press release8/14/2024, 4:32 PM

Demant A/S: Initiation of restructuring plan for EPOS to obtain profitability and continuous commitment to divest the business

Regulatory press release8/1/2024, 9:49 AM

Demant A/S: Restated comparative figures for 2023

Regulatory press release7/16/2024, 4:44 PM

Demant A/S: Revised financial outlook for 2024 and preliminary H1 financial key figures

Regulatory press release6/26/2024, 6:06 AM

Demant A/S: Updated timeline for the strategic review of Communications

Regulatory press release5/21/2024, 6:08 AM

Demant A/S: Closing of divestment of cochlear implants business

Regulatory press release5/6/2024, 5:28 AM

Demant A/S: Interim Management Statement for Q1 2024

Regulatory press release4/8/2024, 10:45 AM

Demant A/S: Completion of capital reduction in Demant A/S

Regulatory press release3/12/2024, 6:30 AM

Demant A/S: Capital Markets Day 2024 - Sharpened focus on Hearing Healthcare

Regulatory press release3/6/2024, 3:33 PM

Demant A/S: Decisions of Annual General Meeting

Regulatory press release2/28/2024, 11:16 AM

Demant A/S: Transactions with Demant shares by Board of Directors and Executive Board and closely related parties

Regulatory press release2/7/2024, 11:59 AM

Demant A/S: Notice of annual general meeting

Regulatory press release2/6/2024, 6:54 AM

Demant A/S: Annual Report 2023 (zip file)

Regulatory press release2/6/2024, 6:31 AM

Demant A/S: Annual Report 2023

Regulatory press release2/5/2024, 4:45 PM

Demant A/S: Results for 2023 and outlook for 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.